CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.
about
Lipid-lowering efficacy of atorvastatinLipid lowering efficacy of atorvastatinStatin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia.[Pharmacogenomic Biomarkers for the Prediction of Statin Efficacy and Safety].APOE polymorphisms contribute to reduced atorvastatin response in Chilean Amerindian subjects.Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugsCYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin.Differentiation of African components of ancestry to stratify groups in a case-control study of a Brazilian urban population.CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid controlEffect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.PharmGKB summary: very important pharmacogene information for CYP3A5.Statin regulation of CYP3A4 and CYP3A5 expression.Genetic determinants of response to statins.Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin.Clinical response to statins: mechanism(s) of variable activity and adverse effects.Lipid-lowing pharmacogenomics in Chinese patients.Seventeen years of statin pharmacogenetics: a systematic review.Prediction of atorvastatin plasmatic concentrations in healthy volunteers using integrated pharmacogenetics sequencing.Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients.CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia.Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.Genetic variation in statin intolerance and a possible protective role for UGT1A1.Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations.
P2860
Q24187301-96E42977-8943-446F-8924-C9298B3FA3DFQ24202363-47BABA62-9C22-4B64-BC5A-3A1C666556C4Q33690357-9779425A-B4CF-4CFF-9F05-5CFA1DD20BC9Q34387744-8DCDD9EA-CCDB-405A-8AA9-1301BE01C808Q35158967-4F5575A5-7EC3-4034-A312-F1FE383DD2ACQ35585570-D1B37505-BD20-46F3-9145-B1CFC50072ADQ35642257-DC54C9D0-F253-4352-9A67-5A3B4EA08DC5Q35933626-3B4C78BF-554B-4258-8B44-E80CC27133BEQ36041632-B36431DC-D3BB-4C91-92CA-51105E8C3F3BQ36927210-F9D20D9D-1B11-4F6E-97AD-2422C3CF8A8EQ37017426-940428EE-824F-4F25-979A-9F0D5D8D22F8Q37081741-4C3129D5-2D46-4C07-BB2C-0E7101F0C6C8Q37521064-A28E84CF-68A9-47D6-8959-F07596A2F88FQ37578563-37EB9786-944F-4A9C-B4E8-AA14E856B3B7Q37646573-1155B091-FDB5-451D-8639-1579894366FCQ37881964-552C4FCB-07EC-4265-9CEA-CFA9A8311286Q38129422-41F6D482-10A7-469E-9E5A-C6622409D81BQ38670109-B5178D3F-E091-46D8-96E6-8FDFBF74D66FQ38782604-5D22777E-B2EB-4E69-B5E0-B1891859E3E2Q42837771-414BB603-E1A0-4C9E-87EC-879BC37EC3C6Q43046014-AD2B4A98-BBE4-41A4-A108-B250E9842C4EQ43826505-0A9453A6-9E5D-43C8-9B5F-93FE8834F3FEQ44502093-519447B4-81A0-4531-82F8-8B7249D5DEDCQ50054110-9FE4E1CE-E95E-4C06-8801-98357BB24D01Q52322328-43DF0301-E4BE-4D65-99CD-FF04E8895C10
P2860
CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
CYP3A53A allele is associated ...... als with hypercholesterolemia.
@en
CYP3A53A allele is associated ...... als with hypercholesterolemia.
@nl
type
label
CYP3A53A allele is associated ...... als with hypercholesterolemia.
@en
CYP3A53A allele is associated ...... als with hypercholesterolemia.
@nl
prefLabel
CYP3A53A allele is associated ...... als with hypercholesterolemia.
@en
CYP3A53A allele is associated ...... als with hypercholesterolemia.
@nl
P2093
P1433
P1476
CYP3A53A allele is associated ...... als with hypercholesterolemia.
@en
P2093
André A Faludi
Egidio L Dorea
Fabiana D V Genvigir
Ivanise M M Rebecchi
Marcelo C Bertolami
Marcia M S Bernik
Maria Alice V Willrich
Mario H Hirata
Rosario D C Hirata
Simone S Arazi
P356
10.1016/J.CCA.2008.07.032
P577
2008-08-05T00:00:00Z